The rising number of immunodeficiency disease cases is anticipated to act as a major driver for the market growth in the coming years, as it enhances the demand for treatments. As PIDD needs long-term therapy (dosage of 500 mg/kg on an average), there has been a significant increase in overall consumption rate (volume of units by patients) among PIDD patients. The existing PID patients are expected to drive the demand for fast, accurate, and safe treatment options, thereby propelling the IVIG market. Moreover, other applications of IVIG in neurological disorders, organ transplantation, and peripheral neuropathies provide a lucrative growth opportunity to the market players. Rise in the incidence of these diseases is expected to drive the penetration of IVIG in the near future, thereby boosting the overall market over the forecast period.
IVIG replacement therapy is used for the treatment of several autoimmune, neurological, and hematological diseases, as well as in immunodeficiency. The U.S. FDA has approved the use of IVIG in various disorders; however, this treatment is also used in many off-prescription disorders such as myasthenia gravis, multifocal motor neuropathy, and Guillain-Barre syndrome. The preference for IVIG is increasing due to its safety and efficacy. Moreover, the alternatives to IVIG, i.e., plasma exchange and corticosteroids, are associated with severe adverse effects; therefore, patients and physicians prefer IVIG. With increase in adoption rate, the IVIG market is anticipated to witness rapid growth over the forecast period. There are over 350 chronic disorders that are categorized as PIDD, and medical therapies are available for over 50% of these conditions. In addition, drugs for treatment of the diseases are covered under Medicare part B and reimbursement is available for home settings as well as physicians' offices, which is anticipated to drive treatment adoption.
The cost of treatment with immunoglobulin is expensive and impedes the overall adoption of IVIG treatment in the U.S. The average cost of treating a CIDP patient every year exceeds USD 136,000, thereby making access to treatment for patients without insurance and Medicare difficult. Furthermore, additional factors influencing the total cost are growing diagnoses of these conditions, with increasing dosage requirements, and high cost of treatment per gram.
This section will provide insights into the contents included in this smart U.S. intravenous immunoglobulin report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
Market drivers and restraints
Key market opportunities prioritized
Latest strategic developments
Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member